Solutions for
in vivo
gene therapy
development

Logo

Solutions for
in vivo
gene therapy
development

By moving cell engineering from the lab into the body, in vivo gene therapy opens new opportunities in the development of cell therapies for multiple diseases, from hematological cancers to autoimmune disorders. Leading modalities like in vivo CAR T therapy reduce the complexity associated with manufacturing personalized ex vivo therapies, which can shorten treatment timelines, improve scalability, and expand patient access. The challenge of in vivo strategies, however, lies in verifying desired cell modifications that now occur in a biologically complex environment. That raises demands on your research tools.

The Miltenyi Biotec portfolio of products and services builds on more than 30 years of cell and gene therapy (CGT) expertise to support every stage of in vivo gene therapy development. Our high-quality solutions for sample preparation and cell separation, flow cytometry, molecular analysis, spatial biology, 2D and 3D imaging, and GMP vector manufacturing standardize your workflows, future-proof your early-stage development analytics, and de-risk your platform.

Trusted globally in CGT development

We bring decades of experience, proven technology, a global presence, and a commitment to advancing cell and gene therapies.

30+

Years of experience in cell and gene therapy, from early development to commercial supply

500+

Batches of GMP lentiviral vectors released, including commercial supply for TECELRA®

200+

Clients supported worldwide, with regulatory submissions in 38 countries

Accelerate your in vivo gene therapy development. Our broad portfolio of integrated solutions and enabling technologies supports the full journey: from target discovery, receptor and vector design, through preclinical validation and vector manufacturing, with biomarker monitoring* to assess performance. Rely on our application expertise, trusted trainings, and technical support for in-house development, or let the CDMO experts at Miltenyi Bioindustry turn your idea into a scalable, regulatory-compliant reality.

Target discovery, receptor & vector design for in vivo gene therapies

In vivo gene therapy development starts with a disease-associated target, an optimized therapeutic construct, and a delivery platform. Use Miltenyi Biotec solutions to confidently identify disease-associated targets of real therapeutic relevance, characterize the target’s expression pattern, and select genetic domains with the desired performance profile.

Our solutions for target discovery, receptor & vector design

Preserve target integrity

Reliable and accurate target analysis relies on intact cells. Prepare samples with gentle enzymatic digestion and optimized storage to preserve cell viability and target biology, so you measure the target and not an artifact of handling.


Relevant products and solutions

Dissociate and store tissues with MACS® Sample Preparation

Screen targets and test recognition

Our flow cytometers are a versatile platform for target selection and optimization. Using pretitrated antibodies, you can standardize marker screening across hundreds of candidates and quantify how well a candidate genetic domain recognizes its target and discriminates non-targets.


Relevant products and solutions

Validate targets in tissue context

Target analysis in the context of tissue architecture reveals the location and type of cells expressing a target. That spatial profiling helps distinguish target-specific binding from off-target interactions. Choose the world’s largest antibody portfolio for spatial biology, and add RNA detection for same-section multiomics.


Relevant products and solutions

Move early to an in vivo–ready vector

Assess your therapeutic gene in a translation-ready construct from the start. Miltenyi Bioindustry provides research-use lentiviral vector material with process development and manufacturing expertise to support vector evaluation, optimization, and translation from early research into development.


Relevant products and solutions

Evaluate vectors on Miltenyi Bioindustry’s lentiviral vector platform

Publication highlight

Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma

Schäfer et al. used flow cytometry screening and spatial analysis on the MACSima Imaging Platform to identify and assess the distribution of target candidates in pancreatic cancer. They narrowed 371 antigens down to four target candidates and 32 CAR constructs and the spatial data helped confirm tumor specificity and informed subsequent preclinical validation.

Schäfer, D. et al. (2021) Nat. Commun. 12: 1453. | Read the article

Publication highlight

Identification and characterization of fully human FOLR1-targeting CAR T cells for the treatment of ovarian cancer

Bethke et al. established a multistep workflow to identify binders of FOLR1-targeting CAR candidates with desirable specificity profiles prior to functional CAR T cell testing. The team screened specificity via flow cytometry and assessed on-target, off-target, and off-tumor reactivity with multiplexed tissue imaging.

Bethke, M. et al. (2024) Cells 13: 1880. | Read the article

Preclinical development for in vivo gene therapies

Before clinical translation, in vivo gene therapies need rigorous preclinical validation of efficient and selective target cell transduction, the desired biological activity, and therapeutic efficacy. Biodistribution, pharmacokinetics, and safety profiles are defined to de-risk more advanced development stages. Our solutions generate the data to evaluate these parameters and inform decisions that progress candidates towards translation.

Our solutions for in vitro characterization

Isolate immune cells from blood

Transduction experiments in whole blood or PBMCs mimic physiological conditions more closely. Isolate the modified and non-modified cell populations you need for analyses directly from complex samples. Our StraightFrom® Technology preserves their integrity and function.


Relevant products and solutions

Get pure, viable cells without preprocessing

Quantify transduced cells

Transduced cell populations may be rare and easily masked in a heterogeneous sample. Combine our flow cytometers with antigen-based reagents, CAR linker antibodies, and CAR idiotype antibodies to detect, phenotype, and quantify cells in a single workflow.


Relevant products and solutions

Quantify vector copy number

Vector copy number (VCN) measures vector integration and helps assess the consistency and safety of a gene-modified product. Our qPCR and dPCR kits help reliably determine VCN and can confirm transduction efficiency as a molecular readout to corroborate flow cytometry results.


Relevant products and solutions

Determine VCN with MACS COPYcheck Kits

Our solutions for in vivo models and ex vivo analysis

Generate humanized mouse models

Test vector performance in the context of human biology. Our tools and resources simplify the generation of humanized mouse models and help you overcome setup and sample complexity to confidently evaluate therapeutic efficacy and safety.


Relevant products and solutions

Generate humanized mouse models with our workflow solutions

Process tissues and isolate human cells

Dissociate tissues into suspensions of highly viable single cells with preserved surface markers. Then, confidently enrich human T cells, T cell subsets, or other populations of interest from mixed-species suspension for downstream functional and molecular analyses.


Relevant products and solutions

Profile immune cells from in vivo studies

Reliably discriminate human from murine cells and characterize transduced cell phenotype and treatment response in humanized mouse tissues and blood samples. Our recombinant antibodies and cytokine assays enable high-resolution profiling via multiparametric flow cytometry analyses.


Relevant products and solutions

Visualize vector distribution and targeting

Confirm the type and tissue location of transduced cells, as well as their ability to reach intended targets or accumulate in off-target tissues. Our spatial imaging portfolio generates detailed visualizations, from single-cell characteristics to tissue and whole-body biodistribution.


Relevant products and solutions

Publication highlight

A novel pseudotype derived of the canine distemper virus for adapter-mediated lentiviral transduction

Miltenyi Biotec and collaborators developed a lentiviral vector derived from canine distemper virus (CDV). A single injection into humanized mice transduced CD4+ and CD8+ T cells efficiently, pointing toward scalable, off-the-shelf CAR T cell therapies.

Winter, N. et al. (2025) Mol. Ther. Methods Clin. Dev. 33: 101526. | Read the article

Publication highlight

CAR-neutrophils produced in vivo to treat glioma

Chang et al. used engineered extracellular vesicles carrying modified RNA to generate CAR neutrophils in vivo. They tracked vesicle distribution in cleared mice using light sheet imaging and demonstrated their colocalization with the targeted neutrophils, down to single-cell resolution.

Chang, Y. et al. (2026) Nat. Biomed. Eng. Epub ahead of print, Apr. 24. | Read the article

Lentiviral vector services for in vivo gene therapy development

Miltenyi Bioindustry offers end-to-end lentiviral vector development and manufacturing for in vivo gene therapy. Vector design, process development, GMP manufacturing and its scale-up come from one partner, taking your program from preclinical research to commercial supply without a handover.

Our lentiviral vector services

A platform for targeted delivery

Our proprietary pseudotyped lentiviral vector platform is derived from canine distemper virus (CDV) and designed for selective delivery with durable gene expression. It offers a pan-T cell variant with optional CD3 display technology for cell activation, plus custom targeting ligands and display proteins for specific cell populations, such as T cell subsets.


Relevant products and solutions

Produce your targeted vector on our lentiviral vector platform

Three ways to work with us

Our lentiviral vector platform flexibly accommodates different development models. You can insert your transgene into our established CDV platform or transfer your existing pseudotype to us for optimization, GMP scale-up, and manufacturing. Alternatively, codevelop a custom CDV variant with your desired targeting and display functions.


Relevant products and solutions

Advance your in vivo program with our lentiviral vector services

GMP manufacturing

Miltenyi Bioindustry offers expert process development from research to the commercial stage. It includes purification steps to minimize host cell DNA and process-related impurities, and GMP manufacturing at 50 and 200 L scales, with technology transfer, process optimization, and end-to-end Chemistry, Manufacturing, and Controls (CMC) support.


Relevant products and solutions

Manufacture your vector under GMP at commercial scale

Rigorous quality

With a focus on residual host cell DNA analysis, vector particle characterization, and product-specific potency assays, our quality assessment of lentiviral vectors ensures reliable performance, demonstrates manufacturing consistency, and supports regulatory compliance.

Biomarker monitoring* for in vivo gene therapy development

In vivo gene therapies shift analytical focus from predosing release testing to the biological events that follow treatment. Performance is assessed by tracking where the vector distributes and how long it persists, which cells are targeted and modified, and how efficiently therapeutic cells are generated. Also important to assess is how well the therapeutic gene is expressed, and how transduced cells expand, function, persist, and drive biological responses. Biomarker analysis is thus integral to development, linking therapeutic product design to biological response and clinical outcome.

Our solutions for biomarker monitoring*

Follow the vector

The same analytics that characterize a vector in development carry over into monitoring*. Vector quality, delivery efficiency, tissue distribution, and persistence tell you whether the therapy reached its target and stayed there.


Relevant products and solutions

Determine VCN and RCL with MACS COPYcheck and LENTIcheck Kits

Track the therapeutic cells

Longitudinal testing for the therapeutic cells pinpoints their emergence, number, phenotype, and durability over time. Additionally, target cell engagement and transgene expression show whether the intended cells were modified and exhibit the desired behavior.


Relevant products and solutions

Read the biological response

Pharmacodynamic markers connect treatment to outcome, while immunogenicity data show how the immune system responds to the therapy and its components. Longitudinal safety signals round out the picture across development and follow-up.

Relevant products and solutions

Connect data to biological insights

Our tools integrate analytical capabilities across development and biomarker monitoring* to transform complex biological data into actionable insights. Connecting therapy concept and vector design with biological response informs key development decisions.

In vivo versus ex vivo gene therapy: What is the difference?


AspectIn vivoEx vivo
Therapy characteristics
Therapeutic principleGenetic modification of cellsGenetic modification of cells
Where cells are engineeredInside the body, after vector administrationOutside the body, in a manufacturing facility
Starting materialNo cell collectionPatient or donor cells, collected by apheresis
Delivery vehiclesTargeted lentiviral vectors, other viral vectors, or lipid nanoparticlesLentiviral or gammaretroviral vectors, or non-viral editing tools
Treatment timelineNo wait for a manufacturing slotWeeks between cell collection and infusion
Supply modelOff-the-shelf drug productMostly patient-specific batches with chain of identity
Research and development challenges
Finding the targetTwo targets to pick: the disease target and the cell type the vector must enterOne target: the disease target on the tumor or tissue
Proving specificityThe vector must not transduce cells other than the intended population, anywhere in the body.The engineered cells must not react against healthy tissue.
Measuring what happenedTransduction efficiency, VCN, transgene expression, measured in samples of treated organismThe same readouts, measured in the cell product before it is infused
Preclinical modelsHumanized mouse models require highly sensitive and robust tools to effectively interrogate the complexity of this model.Humanized mice and in vitro disease models
Made under GMPThe vectorThe vector and the cell product



* The term biomarker monitoring used throughout this webpage refers to longitudinal biomarker analysis during preclinical and clinical research, including investigations of immune responses and cellular dynamics, without any influence on treatment decisions.